‌

US Patent 11584748 Spirocyclic compounds

Patent 11584748 was granted and assigned to C4 Therapeutics on February, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent attributes

Patent Applicant

C4 Therapeutics

Current Assignee

C4 Therapeutics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

February 21, 2023

Patent Application Number

17072896

Date Filed

October 16, 2020

Patent Citations

US Patent 10849982 C3-carbon linked glutarimide degronimers for target protein degradation

US Patent 10351568 Compositions and methods for enhancing proteasome activity

US Patent 10646575 Heterocyclic degronimers for target protein degradation

US Patent 10660968 Spirocyclic degronimers for target protein degradation

US Patent 10905768 Heterocyclic degronimers for target protein degradation

Patent Citations Received

0

US Patent 11802131 Glutarimides for medical treatment

0

Patent Primary Examiner

Charanjit Aulakh

CPC Code

The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11584748 Spirocyclic compounds

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool